Breaking News
Get 40% Off 0
Is NVDA a 🟢 buy or 🔴 sell? Unlock Now

Eli Lilly expands in weight-loss market, Pfizer and AbbVie adjust strategies

Published Nov 21, 2023 06:23AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters.
 
LLY
+0.03%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
PFE
+0.73%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
ABBV
+0.76%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Eli Lilly (NYSE:LLY)'s recent foray into the weight-loss market with the approval of its diabetes drug Mounjaro for weight management signals a strategic expansion for the pharmaceutical giant. Earlier this month, Lilly received regulatory approval for Zepbound, further positioning the company in the competitive weight-loss sector. This move comes as Eli Lilly enjoys significant revenue from Mounjaro, indicating market optimism for its growth potential.

On the same front, Pfizer (NYSE:PFE) is working to counteract a decline in stock value due to reduced demand for its COVID-19 products. The company has embarked on an aggressive rollout plan, introducing 13 new products with a goal of 19 over an 18-month period. This strategy is projected to propel Pfizer's revenue to $84 billion by 2030, a figure that would exceed its earnings prior to the coronavirus pandemic.

AbbVie (NYSE:ABBV), meanwhile, is navigating challenges related to its blockbuster drug Humira losing patent protection, which has impacted revenues. The pharmaceutical firm is offsetting these setbacks with the successful approvals of Rinvoq and Skyrizi for various indications. Sales from these drugs are anticipated to surpass Humira's peak sales within the next four years. AbbVie's broad portfolio, which includes strong performers in neuroscience, oncology, and aesthetics, is expected to support continued growth despite the hurdles faced with Humira.

While Eli Lilly's valuation has increased, reflecting confidence in its future prospects, Pfizer and AbbVie have been highlighted as potentially more attractive investment opportunities due to their current undervaluation. Each company is adapting its strategy to navigate the evolving pharmaceutical landscape and capitalize on new market opportunities.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Eli Lilly expands in weight-loss market, Pfizer and AbbVie adjust strategies
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
Kedar desh
Kedar desh Nov 24, 2023 10:09AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Pfe will hit $40 in one year once diabetics drug gets approval
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email